The company’s late-stage breast cancer development portfolio comprises enobosarm, a selective androgen receptor targeting agonist.
In January 2022, Veru entered into a collaboration and supply agreement with Eli Lilly, with the latter supplying abemaciclib for the ENABLAR-2 trial.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze